These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63 related articles for article (PubMed ID: 7051538)
21. A survey on the efficacy and tolerability of micronized fenofibrate in patients with dyslipidemia. Zhu J; Ye P Chin Med J (Engl); 2003 Jun; 116(6):840-3. PubMed ID: 12877791 [TBL] [Abstract][Full Text] [Related]
22. [Personal experience with 200mg of micronized fenofibrate (Lipanthyl 200 M) in the treatment of primary dyslipidemias]. Vaverková H; Novotný D; Ficker L Vnitr Lek; 1996 Apr; 42(4):239-45. PubMed ID: 8693709 [TBL] [Abstract][Full Text] [Related]
23. Lipid-lowering effects of procetofene. Afschrift M; Mets T; Verdonk G Lancet; 1977 Aug; 2(8032):311. PubMed ID: 69930 [No Abstract] [Full Text] [Related]
24. [The apoB genotype and the efficacy of hypolipidemic therapy]. Tseluĭko VI; Kravchenko NA; Chernyshov Va; Maksimova NA; Nazarenko IL Tsitol Genet; 1998; 32(1):126-34. PubMed ID: 9695263 [TBL] [Abstract][Full Text] [Related]
25. [Fenofibrate, efficacy and tolerance in long-term treatment (author's transl)]. Fromantin M; Gautier D; Quatre JM; Bon R Therapie; 1981; 36(4):473-6. PubMed ID: 7292431 [No Abstract] [Full Text] [Related]
31. [Study of hepatic tolerance after 4 years of treatment with procetofene]. Fromantin M; Drouin P; Sauvanet JP; Rouffy J Nouv Presse Med; 1978 Mar; 7(11):938. PubMed ID: 643562 [No Abstract] [Full Text] [Related]
32. Statins and fibrates in the management of diabetic dyslipidemia. Durrington P Diabet Med; 1997 Jul; 14(7):513-6. PubMed ID: 9223386 [No Abstract] [Full Text] [Related]
33. Fenofibrate and cholestyramine in type II hyperlipoproteinaemia. Lehtonen A; Viikari J Artery; 1982; 10(5):353-67. PubMed ID: 7181678 [TBL] [Abstract][Full Text] [Related]
34. [Pharmacokinetics of fenofibrate in man (author's transl)]. Harvengt C; Desager JP Nouv Presse Med; 1980 Dec; 9(49):3725-7. PubMed ID: 7208337 [TBL] [Abstract][Full Text] [Related]
35. Clinical pharmacokinetics of fenofibrate. Telford M Curr Med Res Opin; 2003; 19(2):139; author reply 139-40. PubMed ID: 12740159 [No Abstract] [Full Text] [Related]
36. Efficacy of lipid-lowering medications in patients treated with clozapine: a naturalistic study. Landry P; Dimitri E; Tessier S; Légaré N J Clin Psychopharmacol; 2008 Jun; 28(3):348-9. PubMed ID: 18480696 [No Abstract] [Full Text] [Related]
37. [One year fenofibrate treatment of type II primary hyperlipidaemia. Effects on lipoproteins and biological tolerance (author's transl)]. Drouin P; Méjean L; Lambert D; Wülfert E; Debry G Nouv Presse Med; 1980 Dec; 9(49):3753-7. PubMed ID: 7208342 [TBL] [Abstract][Full Text] [Related]
38. [Fenofibrate: hypolipaemic activity and safety in long-term treatment. Effects on HDL, LDL, VLDL and apoprotein B in short-term treatment (author's transl)]. Rouffy J; Sauvanet JP; Chanu B; Bakir R; Goy-Loeper J; Saya C; Pinaroli F Nouv Presse Med; 1980 Dec; 9(49):3747-51. PubMed ID: 7208341 [TBL] [Abstract][Full Text] [Related]
39. [Effect of micronized fenofibrate (lipantyl-200M) on synthesis of cholesterol in peripheral blood lymphocytes of patients with ischemic heart disease and hyperlipidemia]. Ivanova TN; Poliakova ED; Olfer'ev AM; Perova NV Biull Eksp Biol Med; 1998 May; 125(5):569-73. PubMed ID: 9644562 [No Abstract] [Full Text] [Related]
40. Rare side-effects of fenofibrate. Rabasa-Lhoret R; Rasamisoa M; Avignon A; Monnier L Diabetes Metab; 2001 Feb; 27(1):66-8. PubMed ID: 11240449 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]